Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review
NCT04609319
·
clinicaltrials.gov ↗
COMPLETED
Status
307
Enrollment
INDUSTRY
Sponsor class
Conditions
Lung Cancer
Interventions
DRUG:
Dacomitinib
Sponsor
Pfizer